tbuckley/cabot-search huggingface dataset:
Dermatology in Epic Poetry—From <i>Beowulf</i> to <i>The Odyssey</i>
Authors: Ajay Kailas
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
US tobacco companies run court ordered advertisements
Authors: Owen Dyer
Journal: BMJ (2017)

Advertisements paid for by America’s biggest tobacco companies appeared on all three major TV networks and in newspapers this week, carrying messages like none the industry has ever broadcast before.

“Cigarette companies intentionally designed cigarettes with enough nicotine to create and sustain addiction,” said one.

“More people die every year from smoking than from murder, AIDS, suicide, drugs, car crashes, and alcohol combined,” noted another.

The advertisements are paid for by Altria, RJ Reynolds Tobacco, Lorillard, and Philip Morris USA. The “corrective statements” they contain were mandated by a landmark federal court decision in 2006.

“Defendants have marketed and sold their lethal product with zeal, with deception, with a single …
Filaggrin inhibits house dust mite phospholipase generation of CD1a lipid antigens for recognition by T cells
Authors: R Jarrett, G Ogg, M Salio, A Lloyd-Lavery, S Subramaniam, E Bourgeois, C Archer, A Cheung, C Hardman, D Chandler, M Salimi, D Gutowska-Owsiak, J B de la Serna, P G Fallon, H Jolin, A Mckenzie, A Dziembowski, E I Podobas, W Bal, D Johnson, D B Moody, V Cerundolo
Journal: British Journal of Dermatology (2016)
TARGIT-U.S.: A registry trial of targeted intraoperative radiation therapy following breast-conserving surgery.
Authors: Michael Alvarado, Etienne Gallant, Janis Scanlon Rice, Stephen R. Grobmyer, Eleanor Elizabeth Harris, Dennis Holmes, Daniel Pavord, William Small
Journal: Journal of Clinical Oncology (2015)

TPS634 Background: The TARGIT-US trial is a pragmatic registry trial for women with clinically localized breast cancers who will undergo breast intraoperative radiation therapy (IORT) as sole radiation therapy post-breast conserving surgery. The TARGIT-A randomized trial of IORT versus whole breast radiation that preceded this trial has published equivalent local control outcomes for these patients (Vaidya et al. Lancet 2013). The objectives of this registry trial, therefore, are to establish eligibility criteria based on previously published trials and studies in order to allow women who meet these criteria to receive IORT on an IRB-approved protocol and to systematically collect and assess acute and long-term toxicity and outcomes in a larger cohort of patients. This will increase the general knowledge regarding this particular form of accelerated partial breast irradiation and allow further assessment of risk groups. Methods: Patients age 45 or older with small ( < 3.5cm) ER+, Her2- tumors planning to ...
Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya
Authors: Ingrid E Lundberg, Anna Tjärnlund
Journal: Annals of the Rheumatic Diseases (2017)

We are grateful for the insightful and highly relevant question raised by Dr Malaviya1 concerning the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. The question concerns autoantibodies, and in particular myositis-specific autoantibodies (MSAs), and why only the anti-Jo-1 autoantibody is included in the new classification criteria.

We understand the concern that was raised and we have discussed the limitation of having limited data on MSAs in our publication.2 This letter gives us a possibility to expand on this limitation and include some more explanations. Our study was initiated more than 10 years ago, and during the last decade we have seen a great advancement in the knowledge of autoantibodies specific for and associated with idiopathic inflammatory myopathies (IIM). This includes identification of several new MSAs, as well as advancement in methods used to detect MSAs that have made it possible to …
My Unfortunate Introduction Into the Financial Toxicity of Cancer Care in America—March Forth
Authors: Fumiko Chino
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer
Authors: Chun-Han Chen, Chun A. Changou, Tsung-Han Hsieh, Yu-Ching Lee, Cheng-Ying Chu, Kai-Cheng Hsu, Hao-Ching Wang, Yu-Chen Lin, Yan-Ni Lo, Yun-Ru Liu, Jing-Ping Liou, Yun Yen
Journal: Clinical Cancer Research (2017)

Purpose: MPT0L145 has been developed as a FGFR inhibitor exhibiting significant anti-bladder cancer activity in vitro and in vivo via promoting autophagy-dependent cell death. Here, we aim to elucidate the underlying mechanisms.Experimental Design: Autophagy flux, morphology, and intracellular organelles were evaluated by Western blotting, transmission electron microscope, and fluorescence microscope. Molecular docking and surface plasmon resonance assay were performed to identify drug-protein interaction. Lentiviral delivery of cDNA or shRNA and CRISPR/Cas9-mediated genome editing was used to modulate gene expression. Mitochondrial oxygen consumption rate was measured by a Seahorse XFe24 extracellular flux analyzer, and ROS level was measured by flow cytometry.Results: MPT0L145 persistently increased incomplete autophagy and phase-lucent vacuoles at the perinuclear region, which were identified as enlarged and alkalinized late-endosomes. Screening of a panel of lipid kinases revealed that MPT0L145 strongly inhibits PIK3C3 with a Kd value of 0.53 nmol/L. Ectopic expression of PIK3C3 reversed MPT0L145-increased cell death and incomplete autophagy. Four residues (Y670, F684, I760, D761) at the ATP-binding site of PIK3C3 are important for the binding of MPT0L145. In addition, MPT0L145 promotes mitochondrial dysfunction, ROS production, and DNA damage, which may in part, contribute to cell death. ATG5-knockout rescued MPT0L145-induced cell death, suggesting simultaneous induction of autophagy is crucial to its anticancer activity. Finally, our data demonstrated that MPT0L145 is able to overcome cisplatin resistance in bladder cancer cells.Conclusions: MPT0L145 is a first-in-class PIK3C3/FGFR inhibitor, providing an innovative strategy to design new compounds that increase autophagy, but simultaneously perturb its process to promote bladder cancer cell death. Clin Cancer Res; 24(5); 1176-89. ©2017 AACR.
Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppression‐associated keratinocyte carcinoma
Authors: C.A. Harwood, S.T. Arron, C.M. Proby, M.M. Asgari, J.N. Bouwes Bavinck, A.C. Green, A.E. Toland
Journal: British Journal of Dermatology (2017)

Linked Articles: Madeleine et al. Br J Dermatol 2017; 177:1208–1216. Harwood et al. Br J Dermatol 2017; 177:1217–1224. Lowenstein et al. Br J Dermatol 2017; 177:1202–1207. Blomberg et al. Br J Dermatol 2017; 177:1225–1233.
Wheat bran decreases prostate cancer in Tramp mice
Authors: John W. Carter, Ron Madl, Dennis Lubahn, Cynthia Besch-Williford, Ruth MacDonald
Journal: Cancer Research (2006)

3932   Dietary antioxidants have potential for preventing or reducing the incidence of several types of cancer. This dietary intervention study investigated a high-antioxidant variety of wheat bran fed to Tramp mice, an animal model of prostate cancer, for 20 weeks. The diets were isocaloric, contained equal amounts of fiber and equal amounts of nitrogen, with the vitamin and mineral mix comparable to the AIN 93G diet. Wheat bran was incorporated in dietary concentrations of 0, 8, 16, and 32%. The control (0%) group included 24 mice and each of the wheat bran groups was composed of 25 mice. There were no differences in terminal body weights or the weights of the entire male reproductive tract, prostate gland, kidneys, liver, brain, testes or testicular fat pad. Prostate tissue was graded on a scale from 1 to 6 (1=normal, 2=low grade prostatic intra-epithelial neoplasia, 3=high grade prostatic intra-epithelial neoplasia, 4=well-differentiated carcinoma, 5=moderately differentiated carcinoma, 6=poorly differentiated carcinoma). Cumulative tissue (tumor) scores ranged from 3.6 to 4.6, with the 16% wheat bran group having the lowest cumulative tumor score. The percentage of animals in each group with prostatic carcinomas ranged from 40 to 60%, with the 16% wheat bran group having the lowest percentage. In conclusion, the results of this study may lead to the development of wheat-containing products for human consumption which may contribute to a reduction in the incidence of prostate cancer. In subsequent investigations we plan to identify specific wheat bran antioxidants responsible for these results.
Abstract 15463: Pioglitazone Enhances Cholesterol Efflux From Macrophages by Increasing ABCA1/ABCG1 Expressions via LXRα/PPARγ Pathway: Findings From in vitro and ex vivo Studies
Authors: Hideki Ozasa, Makoto Ayaori, Masatsune Ogura, Shun-ichi Takiguchi, Kazuhiro Nakaya, Yoshio Terao, Harumi Uto-Kondo, Emi Yakushiji, Maki Iizuka, Makoto Sasaki, Tomohiro Komatsu, Katsunori Ikewaki
Journal: Circulation (2010)

A peroxisome proliferator-activated receptor γ (PPARγ) agonist, pioglitazone (Pio) reduced cardiovascular events in type 2 diabetic patients. ABCA1, which is involved in apolipoprotein A-I (apoA-I)...
Single- and double-tunnel endoscopic submucosal tunnel dissection for large superficial esophageal squamous cell neoplasms
Authors: Wengang Zhang, Yaqi Zhai, Ningli Chai, Enqiang Linghu, Huikai Li, Xiuxue Feng
Journal: Endoscopy (2017)

Single-tunnel endoscopic submucosal tunnel dissection (ESTD) has shown promising preliminary efficacy for large superficial esophageal squamous cell neoplasms (SESCNs). This study reports the outcomes of both single- and double-tunnel ESTD for large SESCNs, and compares the efficiency of the two techniques for treating circumferential SESCNs.46 patients with large SESCNs underwent ESTD at a single hospital between October 2011 and March 2016. Relevant clinical data were retrospectively collected and analyzed.For all patients, the en bloc and R0 resection rates were 95.7 % and 82.6 %, respectively. Perforation and cardiac mucosal laceration were detected in 2.2 % (1/46) and 6.5 % (3/46) of the procedures, respectively. Postoperative stenosis occurred in 12 patients (26.1 %). Of the 18 patients with circumferential lesions, those who received a double-tunnel ESTD procedure (n = 6) underwent dissection faster than those who had a single-tunnel ESTD procedure (n = 12) (0.32 vs. 0.12 cm2/min; P = 0.02).ESTD was effective for large SESCNs. The double-tunnel ESTD appeared to decrease operative time compared with single-tunnel ESTD for circumferential lesions.
Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Authors: Ursula Matulonis, Gerburg M. Wulf, Michael J. Birrer, Shannon Neville Westin, Philippa Quy, Katherine M. Bell-McGuinn, Brian Lasonde, Christin Whalen, Carol Aghajanian, David B. Solit, Gordon B. Mills, Lewis Cantley, Eric P. Winer
Journal: Journal of Clinical Oncology (2014)

2510 Background: In vivo synergy of the PI3-kinase inhibitor BKM120 and the PARP inhibitor olaparib is seen using a mouse model of BRCA1-related breast cancer (BrCa) and sporadic TNBC (Juvekar et al and Ibrahim et al, Cancer Discovery 2012). The PI3kinase pathway is activated in both TNBC and HGSC (www.cancergenome.nih.gov). Olaparib is active in HGSC and germlineBRCA mutation (gBRCAm) ovarian cancer (OvCa) and gBRCAm BrCa. These data were the rationale for this phase I, multi-center study (NCT01623349) combining BKM120 and olaparib in patients (pts) with recurrent HGSC or TNBC. Methods: This study has a 3 + 3 design, escalating dose levels (DL) if 0/3 or 1/6 pts have a dose limiting toxicity (DLT) during the first cycle (1st 28 days). Objectives are to determine the MTD and RP2D of daily oral olaparib (tablet formulation) and BKM120, assess toxicities, preliminary activity of this combination, and PK profiles of both drugs. Planned translational endpts include PI3kinase pathway effects, BRCA1 immunostaining/methylation, IL-8/circulating DNA levels, and somatic mutations in BRCA1/2 using FFPE tissue. Eligibility included: recurrent TNBC or HGSC or any histology of OvCa or BrCa with presence of a gBRCAmut, PS 0-1, and measurable/evaluable cancer. Prior PARP inhibitor use was allowed. Results: 34 pts to date have received study drugs; 9 pts w/TNBC and 25 pts wHGSC. 26 have known gBRCAm. Dosing started at DL1 (BKM120 60 mg and olaparib 100 mg BID); 2 DLTs were observed (1 gr 3 LFTs and 1 gr 3 hyperglycemia). A lower dose (-1) was pursued followed by re-escalation as below. DL 6 was not feasible because of of grade 3 LFTs and grade 3 depression early in cycle 2. Evidence of clinical benefit by RECIST 1.1 was observed on all DL's, and AEs seen were compatible with AE profile of BKM120 and olaparib. Expansion cohorts are accruing. Conclusions: Combined BKM120 and olaparib is feasible with evidence of clinical benefit seen at all DL's. Further studies combining PARP and PI3kinase inhibitors are warranted. Clinical trial information: NCT01623349. Dose level Olaparib dose BID (mg) BKM120 dose qD (mg) # of patients 1 100 60 3 -1 50 40 6 2 100 40 7 3 150 50 3 4A 200 40 3 4B 150 50 3 5A 300 40 3 5B 200 50 3 6 (DLT dose) 300 60 3
Lymph node metastasis in early gastric adenocarcinoma in the United States of America
Authors: Sridevi Pokala, Chao Zhang, Zhengjia Chen, Anthony Gamboa, Sarah Cristofaro, Steven Keilin, Qiang Cai, Field Willingham
Journal: Endoscopy (2017)

Abstract Background and study aims Localized approaches are being increasingly used in the management of early gastric adenocarcinoma; however, there are limited data on lymph node metastasis in the US population. This study examined the incidence and predictors of lymph node involvement for early-stage gastric adenocarcinomas in the USA. Patients and methods Data were abstracted from the national SEER database from 2004 to 2013. Exclusion criteria included: cases with unknown tumor characteristics, unknown patient characteristics, metastatic disease, neoadjuvant radiation, and lack of surgical resection or lymph node evaluation. Univariate and multivariable analyses were conducted to assess the relationship of tumor stage, grade, and size, and patient sex, race, and age with nodal involvement. Results 43 769 cases of gastric adenocarcinoma were initially abstracted. After exclusions, 1577 patients remained for analysis. Multivariable analysis revealed that tumor stage (P &lt; 0.001), grade (P = 0.008), and size (P &lt; 0.001) were independent predictors of nodal metastasis. For low grade T1a tumors, nodal metastasis was present in 1.7 %, 1.7 %, 4.5 %, 4.1 %, and 20 % of tumors 0 – 1 cm, 1 – 2 cm, 2 – 3 cm, 3 – 4 cm, and ≥ 4 cm in size, respectively (P &lt; 0.001), and in 8.4 %, 18.0 %, 19.5 %, 22.0 %, and 35.8 % of T1b tumors, respectively (P &lt; 0.001). Conclusions Low grade T1a tumors &lt; 4 cm in size have low rates of nodal metastasis in the US population and may warrant consideration for local resection. Larger, higher grade T1b tumors have high rates of nodal metastasis in the US population and lymph node dissection may be indicated for patients who are surgical candidates.
Abstract 14069: QSOX1 is Involved in Resolution of Cardiac ER Stress in Mouse
Authors: Anaïs Caillard, Malha Sadoune, Zhenlin Li, Evelyne Polidano, Alexandre Mebazaa, Nicolas Vodovar, Jane-Lise Samuel
Journal: Circulation (2016)

Introduction: QSOX1, a sulfhydryl oxidase involved in the protein folding, is upregulated in acute heart failure. Hypothesis: We hypothesized that QSOX1 could play a role in the endoplasmic reticul...
Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion
Authors: Alessandra M. Richardson, Lauren S. Havel, Allyson E. Koyen, Jessica M. Konen, John Shupe, W.G. Wiles, W. David Martin, Hans E. Grossniklaus, Gabriel Sica, Melissa Gilbert-Ross, Adam I. Marcus
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Vimentin is an epithelial-to-mesenchymal transition (EMT) biomarker and intermediate filament protein that functions during cell migration to maintain structure and motility. Despite the abundance of clinical data linking vimentin to poor patient outcome, it is unclear if vimentin is required for metastasis or is a correlative biomarker. We developed a novel genetically engineered mouse model (GEMM) to probe vimentin in lung adenocarcinoma metastasis. Experimental Design: We used the LSL-KrasG12D/Lkb1fl/fl/Vim−/− model (KLV−/−), which incorporates a whole-body knockout of vimentin and is derived from the Cre-dependent LSL-KrasG12D/Lkb1fl/fl model (KLV+/+). We compared the metastatic phenotypes of the GEMMs and analyzed primary tumors from the KLV models and lung adenocarcinoma patients to assess vimentin expression and function. Results: Characterization of KLV+/+ and KLV−/− mice shows that although vimentin is not required for primary lung tumor growth, vimentin is required for metastasis, and vimentin loss generates lower grade primary tumors. Interestingly, in the KLV+/+ mice, vimentin was not expressed in tumor cells but in cancer-associated fibroblasts (CAFs) surrounding collective invasion packs (CIPs) of epithelial tumor cells, with significantly less CIPs in KLV−/− mice. CIPs correlate with tumor grade and are vimentin-negative and E-cadherin–positive, indicating a lack of cancer cell EMT. A similar heterotypic staining pattern was observed in human lung adenocarcinoma samples. In vitro studies show that vimentin is required for CAF motility to lead tumor cell invasion, supporting a vimentin-dependent model of collective invasion. Conclusions: These data show that vimentin is required for lung adenocarcinoma metastasis by maintaining heterotypic tumor cell–CAF interactions during collective invasion. Clin Cancer Res; 24(2); 420–32. ©2017 AACR.
Glycosylated and non-glycosylated quantum dot-displayed peptides trafficked indiscriminately inside lung cancer cells but discriminately sorted in normal lung cells: An indispensable part in nanoparticle-based intracellular drug delivery
Authors: Roger Salvacion Tan
Journal: Asian Journal of Pharmaceutical Sciences (2017)

Difference in sub-cellular trafficking of glycosylated and naked peptides, between normal and lung cancer cells, was established. Normal lung tissue discriminately sorted glycosylated from non-glycosylated peptides by allowing golgi localization of the glycosylated peptides while restricting golgi entry of the naked peptides. This mechanism was surprisingly not observed in its cancer cell counterpart. Lung cancer cells tend to allow unrestricted localization of both glycosylated and naked peptides in the golgi apparatus. This newly discovered difference in sub-cellular trafficking between normal and lung cancer cells could potentially be used as an effective strategy in targeted intracellular delivery, especially targeting golgi-resident enzymes for possible treatment of diseases associated with glycans and glycoproteins, such as, congenital disease of glycosylation (CDG). This very important detail in intracellular trafficking inside normal and cancer cells is an indispensable part in nanoparticle-based intracellular drug delivery.
IgG response against <i>Staphylococcus aureus</i> is associated with severe atopic dermatitis in children
Authors: J.E.E. Totté, L.M. Pardo, K.B. Fieten, J. de Wit, D.V. de Boer, W.J. van Wamel, S.G.M.A. Pasmans
Journal: British Journal of Dermatology (2017)

An altered immune response against Staphylococcus aureus might contribute to inflammation and barrier damage in atopic dermatitis (AD). To profile IgG antibodies against 55 S. aureus antigens in sera of children with mild‐to‐severe AD and to evaluate the association between IgG levels and disease severity. In this cross‐sectional study, we included children with AD from two interventional study cohorts, the Shared Medical Appointment (SMA) cohort (n = 131) and the older DAVOS cohort (n = 76). AD severity was assessed using the Self‐Administered Eczema Area and Severity Index (SA‐EASI) and levels of thymus and activation‐regulated chemokine (TARC) in serum. IgG antibody levels against 55 S. aureus antigens were quantified simultaneously using a Luminex assay. Pair‐wise correlations were calculated between the 55 IgG levels using the Spearman rank correlation test. Linear regression analysis was performed to test for associations between 55 IgG levels and SA‐EASI and TARC, adjusting for age, sex and S. aureus colonization. In the SMA cohort, 16 antigens were associated with SA‐EASI and 12 with TARC (10 overlapping antigens; P‐values 0·001–0·044). The associated IgG antibodies targeted mainly secreted proteins with immunomodulatory functions. In the DAVOS study, IgG levels against only four and one S. aureus antigen(s) were associated with SA‐EASI and TARC, respectively (no overlap). In young children, severity of AD is associated with an IgG response directed against S. aureus antigens with mainly immunomodulatory functions. These findings encourage further evaluation of the role of S. aureus in the pathogenesis of AD.